细胞外基质
融合蛋白
脂肪性肝炎
纤维化
体内
细胞生物学
化学
维甲酸
癌症研究
生物
生物化学
医学
脂肪肝
病理
基因
维甲酸
疾病
生物技术
重组DNA
作者
Xinzhu Shan,Zhiqiang Zhao,Pingping Lai,Yuxiu Liu,Buyao Li,Yubin Ke,Hanqiu Jiang,Yilong Zhou,Wenzhe Li,Qian Wang,Pengxia Qin,Yizhe Xue,Zihan Zhang,Chenlong Wei,Bin Ma,Wei Liu,Cong Luo,Xueguang Lu,Jiaqi Lin,Li Shu
标识
DOI:10.1038/s41467-024-51571-8
摘要
Abstract Fibrotic diseases, like non-alcoholic steatohepatitis (NASH), pose challenges for targeted delivery and retention of therapeutic proteins due to increased extracellular matrix (ECM) deposition. Here we present a new approach to treat fibrotic diseases, termed “Fibrosis overexpression and retention (FORT)”. In this two-step strategy, we design 1) a retinoid derivative lipid nanoparticle (LNP) to enable specific mRNA overexpression in hepatic stellate cells, and 2) mRNA modifications which facilitate anchoring of therapeutic proteins in the fibrotic ECM. LNPs containing carboxyl retinoid derivatives, as opposed to alcohol or ester retinoid derivatives, effectively delivered mRNA, resulting in more than 10- fold enhancement of protein expression within the fibrotic liver. The carboxyl retinoid rearrangement on the LNP surface improved protein binding, sprouting, and membrane fusion. Therapeutic relaxin fusion proteins were then engineered with an endogenous collagen-binding domain. These fusion proteins exhibited increased retention in fibrotic lesions and reduced systemic side effects. In vivo, fibrosis-targeting LNPs encoding for mRNA fusion proteins demonstrated superior therapeutic efficacy in three clinically relevant NASH mouse models. This approach holds promise in chronic fibrotic diseases that are unsuited for direct injections of recombinant proteins.
科研通智能强力驱动
Strongly Powered by AbleSci AI